-

Tandem Diabetes Care Appoints Mark Novara as EVP and Chief Commercial Officer

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced the appointment of Mark Novara as Executive Vice President and Chief Commercial Officer, effective November 13, 2023. Mr. Novara comes to Tandem with extensive global healthcare experience, having served in the diabetes, medical technology, and life sciences industries for nearly 25 years.

“Mark is a strategic, global leader with a successful track record of driving above market business growth, while building scalable commercial operations and delivering best-in-class customer experience,” said John Sheridan, president and CEO. “We welcome Mark to our leadership team at this exciting stage in Tandem’s evolution, as we prepare to expand our family of innovative technologies and execute on our shared vision to improve the lives of people with diabetes.”

“I was drawn to Tandem’s mission-driven commitment to innovation and their customer-centric culture,” said Mr. Novara. “Tandem has a strong portfolio powered by Control-IQ technology that provides compelling clinical results for people living with diabetes. I am excited to be joining Tandem at this pivotal time and look forward to working closely with the team to build on its strong foundation through new product launches, commercial excellence and global expansion.”

Mr. Novara joins Tandem Diabetes Care from McKinsey & Company, where he served as Senior Advisor in the Medical Technology/Life Science practice since February 2023. Before that time, Mr. Novara held executive positions at Becton Dickinson for more than a decade, most recently serving as Worldwide Vice President and General Manager in Medication Delivery Solutions, as Senior Vice President, Global Strategic Marketing for the Medical and Life Sciences Segments, and as Worldwide Vice President and General Manager in Diabetes Care. He also held leadership positions with Roche and Sanofi-Aventis. Mr. Novara received a BS in Biology from Villanova University, and a Masters in Healthcare Management from Columbia University.

About Tandem Diabetes Care, Inc.

Tandem Diabetes Care, Inc., a global insulin delivery and diabetes technology company based in San Diego, California, creates new possibilities for people living with diabetes, their loved ones, and healthcare providers through a positively different experience. The company’s human-centered approach to design, development, and support delivers innovative products and services for people who use insulin. Tandem manufactures and sells the t:slim X2 pump with Control-IQ technology. For more information, visit tandemdiabetes.com.

Follow Tandem Diabetes Care on Twitter @tandemdiabetes; use #tslimX2 and #TandemDiabetes.
Follow Tandem Diabetes Care on Facebook at facebook.com/TandemDiabetes.
Follow Tandem Diabetes Care on LinkedIn at linkedin.com/company/tandemdiabetes.

© 2023 Tandem Diabetes Care, Inc. All rights reserved. Tandem Diabetes Care, the Tandem logo, Control-IQ, Tandem Mobi and t:slim X2 are either registered trademarks or trademarks of Tandem Diabetes Care, Inc. in the United States and/or other countries. All third-party marks are the property of their respective owners.

Contacts

Media Contact:
858-255-6388
media@tandemdiabetes.com

Investor Contact:
858-366-6900
IR@tandemdiabetes.com

Tandem Diabetes Care, Inc.

NASDAQ:TNDM

Release Versions

Contacts

Media Contact:
858-255-6388
media@tandemdiabetes.com

Investor Contact:
858-366-6900
IR@tandemdiabetes.com

Social Media Profiles
More News From Tandem Diabetes Care, Inc.

Tandem Diabetes Care Launches t:slim X2 Insulin Pump Compatibility with Abbott FreeStyle Libre 3 Plus Sensor in Five International Markets

SAN DIEGO--(BUSINESS WIRE)--The t:slim X2™ insulin pump from Tandem Diabetes Care is now compatible with Abbott’s FreeStyle Libre 3 Plus CGM sensor in five EU countries....

Tandem Diabetes Care to Announce Second Quarter 2026 Financial Results on August 6, 2026

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, plans to release its second quarter 2026 results after the financial markets close on Thursday, August 6, 2026. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its second quarter 2026 financial and operating results.A live webcast of the call will be available on Tandem Diabet...

Tandem Diabetes Care Automated Insulin Delivery Systems Receive CE Mark for Type 2 Diabetes and Type 1 Diabetes During Pregnancy

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care receives CE mark for AID systems in Europe to include use in type 1 diabetes during pregnancy and adults with type 2 diabetes....
Back to Newsroom